Article
24 Jun 2026
Teva Launches AHZANTIVE® Aflibercept Biosimilar In Europe
AUTHORS CONTENT
Article
27 Apr 2026
FDA Issues Draft Guidance On Safety Testing For Gene Editing Therapies
Article
22 Apr 2026
FDA Releases Congressional Justification For FY 2027 Budget, Including Proposal Regarding Interchangeability Of Biosimilars
Article
14 Apr 2026
Teva Receives FDA Approval Of Denosumab Biosimilar And Filing Acceptances By FDA And EMA For Omalizumab Biosimilar
Article
10 Mar 2026
European Biosimilar Updates
Article
08 Jan 2026
Celltrion And Sandoz Launch Their Aflibercept Biosimilars In Europe
Article
02 Jan 2026
Sun Pharma Launches ILUMYA® In India
Article
31 Dec 2025
CareFirst's Class Action STELARA® Antitrust Case Against J&J Will Proceed: Court Grants-in-Part And Denies-in-Part Class Certification And Denies The Parties' Motions For Summary Judgment
Article
29 Dec 2025
Regeneron Seeks To Bifurcate Or Stay Amgen's Antitrust Claims In Aflibercept Patent Litigation
Article
24 Nov 2025
Regeneron Moves To Strike And Dismiss Amgen's Counterclaims In Aflibercept Litigation
Article
16 Sep 2025
Would Exercising March-in Rights Lower Biologic Prices?
Article
08 Sep 2025
FDA Approves Denosumab Biosimilars BILDYOS And BILPREVDA
Article
19 Aug 2025
PTAB Discretionarily Denies Two Petitions, Refers A Third To The Board In Amgen v. Bristol-Myers Squibb
Article
15 Jul 2025
Denosumab Updates: Wyost And Jubbonti Launch As First Denosumab Biosimilars In The U.S.
Article
08 Jul 2025
EMA Adopts Positive Opinions For Multiple Biosimilars
Article
25 Jun 2025
Regeneron Files Another Complaint Against Amgen In Aflibercept BPCIA Litigation
Article
02 Jun 2025
Biogen Files Suit Against Neurimmune Over Rights To Bispecific Antibody
Article
22 May 2025
HyClone Seeks To Quash Amgen's Subpoena Issued In Amgen/Accord Denosumab BPCIA Litigation
Article
30 Apr 2025
Regeneron, Mylan, And Biocon Settle In Aflibercept BPCIA Litigation
Article
19 Mar 2025
Federal Circuit Affirms Denial Of Injunction Against Amgen In Aflibercept BPCIA Litigation